

CORRECTION

Open Access



Correction to: LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis

Yue Wu^{1,2†}, Ting Wang^{1,2†}, Lin Xia³ and Mei Zhang^{1,2*}

Correction: *Cancer Cell Int* (2021) 21:284
<https://doi.org/10.1186/s12935-021-01993-x>

In the original article, the author would like to make the below changes in bold.

Western blotting.

RIPA buffer (Sigma, USA) was used **to isolate protein**, and these proteins were then separated by 10% SDS-PAGE, transferred to PVDF membranes (Millipore, MA, USA),

Results.

The levels of lncRNA WDFY3AS2 in OC cells with different levels of cisplatin sensitivity.

SDC4 expression in A2780-DDP cells was inhibited by the miR-139-5p mimic, while SDC4 expression was **increased** in the miR-139-5p inhibitor group (Fig. 5C, D, $P < 0.001$). The correlation analysis demonstrated that SDC4 expression was negatively correlated with miR-139-5p ($r = -0.6851$, $P < 0.01$ Fig. 5E). These findings indicated that SDC4 was targeted by miR-139-5p negatively.

Furthermore, co-transfection of the miR-139-5p inhibitor could rescue the SDC4 expression reduced by si-WDFY3-AS2 in A2780-DDP cells (Fig. 5E,G, $P < 0.001$).

The weights and volumes of tumors in animals that had been administered the miR-139-5p inhibitor or SDC4 were notably increased relative to the si-WDFY3-AS2 mice (all $P < 0.001$, Fig. 7D-F).

We found that overexpression of the WDFY3-AS2 increased cell viability, migration, and invasion, inhibited apoptosis, as well as OC CSC traits induction, as shown by induced tumor sphere formation, **CD44**-, **CD166**-positive cell numbers, and the expression levels of CSC markers both in vitro and in vivo.

Accepted: 1 August 2023

Published online: 23 August 2023

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1186/s12935-021-01993-x>.

*Correspondence:

Mei Zhang

zhangmei@ahmu.edu.cn

¹Department of Integrated Chinese and Western Medicine Oncology, The First Affiliated Hospital of Anhui Medical University, No. 218, Jixi Road, Hefei 230022, Anhui, China

²The Traditional and Western Medicine (TCM)-Integrated Cancer Center of Anhui Medical University, 81 Meishan Road, Hefei 230032, China

³Graduate School of Anhui, University of Traditional Chinese Medicine, Hefei 230012, Anhui, China



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.